MedPath

BLISOVI FE 1.5/30

Blisovi Fe 1.5/30(norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets*)1.5 mg/0.03 mg*Ferrous Fumarate Tablets are not USP for dissolution

Approved
Approval ID

a0ba9371-46c5-4291-8409-491911e255ab

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 14, 2023

Manufacturers
FDA

Lupin Pharmaceuticals, Inc.

DUNS: 089153071

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

norethindrone acetate and ethinyl estradiol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68180-866
Application NumberANDA201585
Product Classification
M
Marketing Category
C73584
G
Generic Name
norethindrone acetate and ethinyl estradiol
Product Specifications
Effective DateDecember 14, 2023
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BLISOVI FE 1.5/30 - FDA Drug Approval Details